ProKidney Dividends and Buybacks
Dividend criteria checks 0/6
ProKidney does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-28.0%
Buyback Yield
| Total Shareholder Yield | -28.0% |
| Future Dividend Yield | 0% |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
Recent updates
2025 Will Be A Major Year For ProKidney's Rilparencel In CKD Treatment
Jan 31We're Hopeful That ProKidney (NASDAQ:PROK) Will Use Its Cash Wisely
Nov 18
We're Not Very Worried About ProKidney's (NASDAQ:PROK) Cash Burn Rate
Aug 12We Think ProKidney (NASDAQ:PROK) Can Afford To Drive Business Growth
May 12Here's Why We're Not Too Worried About ProKidney's (NASDAQ:PROK) Cash Burn Situation
Nov 17ProKidney (NASDAQ:PROK) Is In A Strong Position To Grow Its Business
Mar 14ProKidney reports Q2 2022 results
Aug 11Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if PROK's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PROK's dividend payments have been increasing.
Dividend Yield vs Market
| ProKidney Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (PROK) | n/a |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.4% |
| Industry Average (Biotechs) | 2.4% |
| Analyst forecast (PROK) (up to 3 years) | 0% |
Notable Dividend: Unable to evaluate PROK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PROK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate PROK's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as PROK has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/02 07:29 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ProKidney Corp. is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Yigal Nochomovitz | Citigroup Inc |
| Vamil Divan | Guggenheim Securities, LLC |